Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

UroGen Pharma (URGN) Other Gross PP&E Adjustments (2016 - 2025)

UroGen Pharma's Other Gross PP&E Adjustments history spans 10 years, with the latest figure at -$13.4 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 60.47% year-over-year to -$13.4 million; the TTM value through Dec 2025 reached -$13.4 million, down 60.47%, while the annual FY2025 figure was -$13.4 million, 60.47% down from the prior year.
  • Other Gross PP&E Adjustments reached -$13.4 million in Q4 2025 per URGN's latest filing, down from -$183000.0 in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $3.8 million in Q3 2024 to a low of -$13.4 million in Q4 2025.
  • Average Other Gross PP&E Adjustments over 5 years is $392000.0, with a median of $2.2 million recorded in 2021.
  • Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 606.87% in 2021, then plummeted 550.28% in 2023.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $3.0 million in 2021, then crashed by 33.79% to $2.0 million in 2022, then tumbled by 550.28% to -$9.0 million in 2023, then rose by 7.0% to -$8.4 million in 2024, then crashed by 60.47% to -$13.4 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Other Gross PP&E Adjustments are -$13.4 million (Q4 2025), -$183000.0 (Q3 2025), and $780000.0 (Q2 2025).